WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...